title: Monitoring of peripheral blood CD34+ cell counts on the first day of apheresis is highly predictive for efficient CD34+ cell yield.
abstract: The purpose of this study was to evaluate the correlation of preleukapheresis circulating CD 34+ cells/micro L, white blood cells (WBC), and platelet counts on the first day of apheresis with the yield of collected CD 34+ cell counts in 40 patients with hematological malignancies (n = 29) and solid tumors (n = 11). The median numbers of apheresis cycles, numbers of CD 34+ cells, peripheral blood (PB) mononuclear cells, and total nucleated cells collected were 2 (range, 1-4), 5.5 x 106/kg (range, 0.05-33.78), 2.59 x 108/kg (range, 0.04-20.68), and 7.36 x 108/kg (range, 0.15-28.08), respectively. There was a strong correlation between the number of preleukapheresis circulating CD 34+ cells/micro L and the yield of collected CD 34+ cells per kilogram (r = 0.962, p < 0.001). The threshold levels of PB C 34+ cell/micro L to obtain > or =1 x 106/kg and > or =2.5 x 106/kg CD 34+ cell in one collection were 12/micro L and 34/ micro L, respectively. Fifteen of 17 (88%) patients who had > or =34 CD 34+ cells/ micro L in the PB before collection reached the level of > or =2.5 x 106/kg in a single apheresis. Despite a low r value, WBC and platelet counts on the first day of apheresis also correlated with the yield of collected daily CD 34+ cells per kilogram (r = 0.482, p < 0.01 and r = 0.496 p < 0.01, respectively). These data suggest that preleukapheresis circulating CD 34+ cells/ micro L correlated significantly better with the yield of collected CD 34+ cells than WBC and platelet counts on the first day of apheresis. Using a value of 34/micro L preleukapheresis circulating CD 34+ cells as a guide for the timing of peripheral blood stem cells collections can be time saving and cost-effective.
authors.affiliation: Ankara University Medical School, Department of Hematology/Oncology and Bone Marrow Transplant, Ankara, Turkey. demirer@medicine.ankara.edu.tr
authors.forename: Taner
authors.initials: T
authors.lastname: Demirer
authors.forename: Osman
authors.initials: O
authors.lastname: Ilhan
authors.forename: Meltem
authors.initials: M
authors.lastname: Ayli
authors.forename: Mutlu
authors.initials: M
authors.lastname: Arat
authors.forename: Mehmet
authors.initials: M
authors.lastname: Dagli
authors.forename: Muhit
authors.initials: M
authors.lastname: Ozcan
authors.forename: Rauf
authors.initials: R
authors.lastname: Haznedar
authors.forename: Yasemin
authors.initials: Y
authors.lastname: Genc
authors.forename: Turgay
authors.initials: T
authors.lastname: Fen
authors.forename: Erol
authors.initials: E
authors.lastname: Ayyildiz
authors.forename: Suleyman
authors.initials: S
authors.lastname: Dincer
authors.forename: Onder
authors.initials: O
authors.lastname: Arslan
authors.forename: Gunhan
authors.initials: G
authors.lastname: Gurman
authors.forename: Nahide
authors.initials: N
authors.lastname: Konuk
authors.forename: Klara
authors.initials: K
authors.lastname: Dalva
authors.forename: Akin
authors.initials: A
authors.lastname: Uysal
authors.forename: Haluk
authors.initials: H
authors.lastname: Koc
authors.forename: Gulsum
authors.initials: G
authors.lastname: Ozet
authors.forename: Hamdi
authors.initials: H
authors.lastname: Akan
mesh_terms: D000293:Adolescent; D000328:Adult; D018952:Antigens, CD34 / Q000097:blood*; D001800:Blood Specimen Collection; D006689:Hodgkin Disease / Q000097:blood / Q000628:therapy; D006801:Humans; D007937:Leukapheresis; D008223:Lymphoma / Q000097:blood / Q000628:therapy*; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000628:therapy; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D009101:Multiple Myeloma / Q000097:blood / Q000628:therapy; D009504:Neutrophils; D010976:Platelet Count
chemical_list: D018952:Antigens, CD34